(CAD)
Q4 2025
% Changevs.Q4 2024
FY 2025
% Change vs. FY 2024
Canadian Pharma Sales
8,792,653
+3
%
37,143,783
+13
%
International Pharma Sales
601,387
+240
%
3,735,959
+302
%
Legacy Business Sales
277,883
+278
%
2,172,241
+86
%
Total Company Sales
9,671,923
+10
%
43,051,983
+23
%
EBITDA1
2,528,561
+13
%
12,122,756
+30
%
Net Income After Taxes (NIAT)
1,991,788
+23
%
9,012,232
+24
%
Fully Diluted EPS
0.17
+25
%
0.78
+27
%
Return on Average Equity for FY 2025 was 24% as compared to 21% for FY 2024
During FY 2025, repurchased for cancellation a total of 19,500 common shares under a Normal Course Issuer Bid (NCIB)
Paid quarterly cash dividends of $0.05 per common share on March 14, 2025, June 13, 2025, September 15, 2025, and December 15, 2025
Increased quarterly dividend by 10% to $0.055 per common share - paid on March 13, 2026
Generated $2.4 million in sales in 2025 from international Tibelia® (tibolone) assets acquired in 2024
Completed acquisition of Oral Science Inc., a Canadian owner and distributor of specialized dental hygiene and oral health products, as announced on March 2, 2026
"We finished 2025 with double-digit overall revenue growth in the fourth quarter with continued growth in our Canadian pharmaceutical business and sizable contributions from our international Tibelia® business and legacy business," commented Mr. René Goehrum, President and CEO of BioSyent. "For the full year, we are proud to have delivered 23% total Company revenue growth while maintaining a healthy 21% NIAT margin. We continue to invest in our FeraMAX® and Tibella® / Tibelia® products which were significant drivers of revenue and profit growth both in Canada and internationally during the year. We also continued to invest in our growing Inofolic® launch product during the year. Our mature brands, Cathejell®, RepaGyn® and Protect-It® continued to deliver profit and cash flows with narrow ongoing investment. BioSyent's track record of 62 consecutive profitable quarters and capital-light, cash-flowing business model have enabled us to build a strong balance sheet and afforded us with maximum flexibility in capital allocation decisions. We are pleased to have deployed our hard-earned capital in our recent acquisition of Oral Science Inc. and we are eager to continue to grow this newly-acquired oral health business along with our pharmaceutical business. We will continue to invest in growth and product diversification in both of these businesses while returning capital to shareholders through share buybacks and regular cash dividends. I look forward to sharing our progress throughout 2026."
The CEO's presentation on the Q4 and FY 2025 Results is available at the following link: www.biosyent.com/investors/
The Company's Audited Consolidated Financial Statements and Management's Discussion and Analysis for the fourth quarter and full year ended December 31, 2025 and 2024 will be posted on www.sedarplus.ca on March 19, 2026.
For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty healthcare company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its Canadian pharma, international pharma, and oral health business units.
As of the date of this press release, the Company has 11,497,447 common shares outstanding.
BioSyent Inc.
Consolidated Statements of Comprehensive Income
In Canadian Dollars
Q4 2025
Q4 2024
% Change
FY 2025
FY 2024
% Change
Net Revenues
9,671,923
